MarketPulse

IgA nephropathy

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Complement Inhibitors Market Set for Robust Growth Through 2036 as C5, C3 Therapies Expand

Complement inhibitors market projected for strong growth through 2036, driven by rising disease prevalence and C5/C3-targeted drug approvals across multiple indications.
NVSSNYRHHBYAZNREGN+3clinical trialsmarket growth
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

IgA Nephropathy Market Set to Nearly Quadruple by 2036 Amid Novel Therapy Wave

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.
NVSVRTXRHHBYAZNTAK+4clinical trialsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Jade Biosciences Names Chief Medical Officer, Awards $12.7M Stock Option Grant

Clinical-stage biotech Jade Biosciences appoints Dr. Edward Conner as CMO, grants 500,000 stock options valued at $12.7M as inducement under Nasdaq rules.
JBIOautoimmune diseasesclinical-stage biotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Novartis

Novartis Fabhalta Shows 49% Slowing of Kidney Decline in Landmark IgAN Study

Novartis' Fabhalta slowed kidney function decline by 49.3% in Phase III trial, with FDA priority review granted for IgA nephropathy treatment.
NVSFDA approvalkidney disease
The Motley FoolThe Motley Fool··Adria Cimino

Vertex Pharma's $600 Target Hinges on Diversification Beyond Cystic Fibrosis

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.
VRTXbiotechrevenue growth
GlobeNewswire Inc.GlobeNewswire Inc.··Jade Biosciences, Inc.

Jade Biosciences Posts $127.4M Loss, Eyes 2028 Cash Runway With Pipeline Catalysts

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.
JBIOmonoclonal antibodyclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Vera Therapeutics Bolsters Board with Royalty Pharma Executive Ahead of Key Drug Launch

Vera Therapeutics appoints Christopher Hite, Royalty Pharma EVP, to board as the biotech prepares for atacicept launch in IgA nephropathy treatment.
RPRXVERAbiopharmaceuticalIgA nephropathy
BenzingaBenzinga··Vandana Singh

Novartis Kidney Drug Demonstrates Sustained Efficacy in Long-Term Study Data

Novartis's kidney drug Vanrafia shows sustained efficacy in slowing kidney function decline, supporting its path to full regulatory approval in 2026 for IgA nephropathy treatment.
NVSkidney diseaseEGFR